The global protein expression market size was estimated to be USD 3.34 billion in 2023 and is expected to reach at USD 13.69 billion by 2034 with a CAGR of 13.68% during the forecast period 2024-2034. Rising significance of protein-based therapeutics, growing investment by biopharmaceutical companies in research & development activities, increasing demand for personalized therapeutics, surge in research & development activities, rising advancement in technology, growing technological advancements, surge in launch of advanced products, and increasing number of mergers and acquisitions among market competitors are some of the key factors boosting the market growth.
Increasing number of mergers and acquisitions among market competitors is predicted to boost the market growth during the forecast period. The progress in genetic engineering and recombinant technology has opened up abundant prospects for producing and segregating foreign proteins, serving scientific, medical, and industrial purposes. Thanks to significant advancements in biotechnology, it is now possible to achieve large-scale production and extraction of recombinant proteins. These systems for protein expression, often known as production systems, are widely utilized in biotechnology, healthcare, and the life sciences sectors. For instance, in August 2022, BioIVT declared the purchase of Cypex, citing that the assortment of proteins from the acquired company aligns effectively with BioIVT's offerings for advancing drug research and development. Additionally, Cypex's products are generated using patented technology enabling the expression of human drug-metabolizing enzymes in bacteria, without significant protein alterations.
By expression system, prokaryotic was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the beneficial characteristics, such as the huge scale of recombinant protein production in a short period & at a cheaper cost, make it relatively easier to manage & fulfil important research aims and increasing investment for research & development activities by major market players. For instance, in July 2022, Beijing Luzhu Biotechnology and Maxvax Biotechnology are in the process of raising funds for their individual research and development initiatives aimed at creating a vaccine. Maxvax recently secured about $74 million through Series B funding to back numerous clinical trials for its range of vaccine candidates. The company possesses diverse technologies, including recombinant protein expression and mRNA platforms, which are utilized worldwide. Additionally, mammalian cell is predicted to grow at fastest CAGR during the forecast period owing to the growing need from pharmaceutical firms for mammalian expression systems for development and manufacture protein temporarily or fully developed cell lines and rising preference of mammalian cells for vaccines, therapeutics, & proteins productions.
By product, reagents was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the increasing demand of reagents for cell culture, rising research on cell-free systems, and surge in launch of innovative products. For instance, in May 2022, QIAGEN has completed the acquisition of BLIRT, a company specializing in recombinant enzymes production. This acquisition has introduced highly synergistic capabilities to QIAGEN, opening up new avenues for growth in the enzymes and reagents sector. Additionally, services is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of protein production & expression are being outsourced by pharmaceutical & biotech businesses to antibody manufacturing companies in order to assist the development of their own assays & the search for therapeutic antibodies.
By application, therapeutic was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the rising corporate involvement in creating protein-based medicines, increasing approvals by regulatory bodies, growing collaborations within market players, and surge in funding for research by major market players. For instance, in July 2022, Vicinitas Therapeutics, a biotechnology firm that utilizes its unique targeted protein stabilization platform to create innovative treatments for cancer and genetic disorders, commenced its operations with $65 million in Series A funding. Additionally, research is predicted to grow at fastest CAGR during the forecast period owing to the growing investment in research & development activities and growing focus on development of novel products.
By end-user, pharmaceutical & biotechnological companies was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the rising use of cultivated cells for the production of therapies and personalised medications, increasingly creative uses of proteins are being made in the pharmaceutical sector, growing introduction of new products, and surge in initiatives by market players. For instance, in June 2022, Codex DNA, Inc., a synthetic biology company based in the United States, has disclosed its plans to showcase its BioXp system and RapidAMP technology for antibody and protein engineering processes at the Antibody Engineering and Therapeutics Europe Conference scheduled for June 7 to 9, 2023. The BioXp system offers a fully automated, hands-free solution for DNA assembly, cloning, amplification, and mRNA synthesis in a single operation. Additionally, contract research organizations is predicted to grow at fastest CAGR during the forecast period owing to the variety of professional services offered by the organizations at cost-effective rates to the pharmaceutical and biopharmaceutical firms.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in funding for research & development activities, rising collaboration within market players & academic institutions, growing healthcare infrastructure, increasing usage of protein technologies, the presence of major market players, surge in research studies on protein engineering, and rising product launches. For instance, in May 2022, Abevmy (bevacizumab) has been introduced to the Canadian market, according to Biocon Biologics Ltd. and Viatris Inc. This marks the fourth cancer-related biosimilar brought to Canada by Viatris. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of protein expression in various applications, increasing focus on proteomics & genomics research, rising initiatives by academic institutions for development of innovative protein therapeutics, and surge in collaborations within market players. For instance, in May 2023, The World Health Organization (WHO) and the Republic of Korea have entered into an agreement through a Memorandum of Understanding (MOU) to create a global training center for biomanufacturing. This international training hub is intended to support lower- and middle-income nations by offering knowledge and skills in producing biological substances like vaccines, insulin, monoclonal antibodies, and therapies for cancer.
Increasing number of mergers and acquisitions among market competitors is predicted to boost the market growth during the forecast period. The progress in genetic engineering and recombinant technology has opened up abundant prospects for producing and segregating foreign proteins, serving scientific, medical, and industrial purposes. Thanks to significant advancements in biotechnology, it is now possible to achieve large-scale production and extraction of recombinant proteins. These systems for protein expression, often known as production systems, are widely utilized in biotechnology, healthcare, and the life sciences sectors. For instance, in August 2022, BioIVT declared the purchase of Cypex, citing that the assortment of proteins from the acquired company aligns effectively with BioIVT's offerings for advancing drug research and development. Additionally, Cypex's products are generated using patented technology enabling the expression of human drug-metabolizing enzymes in bacteria, without significant protein alterations.
By expression system, prokaryotic was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the beneficial characteristics, such as the huge scale of recombinant protein production in a short period & at a cheaper cost, make it relatively easier to manage & fulfil important research aims and increasing investment for research & development activities by major market players. For instance, in July 2022, Beijing Luzhu Biotechnology and Maxvax Biotechnology are in the process of raising funds for their individual research and development initiatives aimed at creating a vaccine. Maxvax recently secured about $74 million through Series B funding to back numerous clinical trials for its range of vaccine candidates. The company possesses diverse technologies, including recombinant protein expression and mRNA platforms, which are utilized worldwide. Additionally, mammalian cell is predicted to grow at fastest CAGR during the forecast period owing to the growing need from pharmaceutical firms for mammalian expression systems for development and manufacture protein temporarily or fully developed cell lines and rising preference of mammalian cells for vaccines, therapeutics, & proteins productions.
By product, reagents was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the increasing demand of reagents for cell culture, rising research on cell-free systems, and surge in launch of innovative products. For instance, in May 2022, QIAGEN has completed the acquisition of BLIRT, a company specializing in recombinant enzymes production. This acquisition has introduced highly synergistic capabilities to QIAGEN, opening up new avenues for growth in the enzymes and reagents sector. Additionally, services is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of protein production & expression are being outsourced by pharmaceutical & biotech businesses to antibody manufacturing companies in order to assist the development of their own assays & the search for therapeutic antibodies.
By application, therapeutic was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the rising corporate involvement in creating protein-based medicines, increasing approvals by regulatory bodies, growing collaborations within market players, and surge in funding for research by major market players. For instance, in July 2022, Vicinitas Therapeutics, a biotechnology firm that utilizes its unique targeted protein stabilization platform to create innovative treatments for cancer and genetic disorders, commenced its operations with $65 million in Series A funding. Additionally, research is predicted to grow at fastest CAGR during the forecast period owing to the growing investment in research & development activities and growing focus on development of novel products.
By end-user, pharmaceutical & biotechnological companies was the highest revenue-grossing segment in the global protein expression market in 2023 owing to the rising use of cultivated cells for the production of therapies and personalised medications, increasingly creative uses of proteins are being made in the pharmaceutical sector, growing introduction of new products, and surge in initiatives by market players. For instance, in June 2022, Codex DNA, Inc., a synthetic biology company based in the United States, has disclosed its plans to showcase its BioXp system and RapidAMP technology for antibody and protein engineering processes at the Antibody Engineering and Therapeutics Europe Conference scheduled for June 7 to 9, 2023. The BioXp system offers a fully automated, hands-free solution for DNA assembly, cloning, amplification, and mRNA synthesis in a single operation. Additionally, contract research organizations is predicted to grow at fastest CAGR during the forecast period owing to the variety of professional services offered by the organizations at cost-effective rates to the pharmaceutical and biopharmaceutical firms.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in funding for research & development activities, rising collaboration within market players & academic institutions, growing healthcare infrastructure, increasing usage of protein technologies, the presence of major market players, surge in research studies on protein engineering, and rising product launches. For instance, in May 2022, Abevmy (bevacizumab) has been introduced to the Canadian market, according to Biocon Biologics Ltd. and Viatris Inc. This marks the fourth cancer-related biosimilar brought to Canada by Viatris. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of protein expression in various applications, increasing focus on proteomics & genomics research, rising initiatives by academic institutions for development of innovative protein therapeutics, and surge in collaborations within market players. For instance, in May 2023, The World Health Organization (WHO) and the Republic of Korea have entered into an agreement through a Memorandum of Understanding (MOU) to create a global training center for biomanufacturing. This international training hub is intended to support lower- and middle-income nations by offering knowledge and skills in producing biological substances like vaccines, insulin, monoclonal antibodies, and therapies for cancer.
Segmentation: Protein Expression Market Report 2022 - 2033
Protein Expression Market Analysis & Forecast by Expression System 2023 - 2034 (Revenue USD Bn)
- Insect Cell
- Prokaryotic
- Yeast
- Mammalian Cell
- Others
Protein Expression Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Competent Cells
- Reagents
- Services
- Instruments
- Expression Vectors
Protein Expression Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Industrial
- Research
- Therapeutic
Protein Expression Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academic Research
- Contract Research Organizations
- Pharmaceutical & Biotechnological Companies
- Others
Protein Expression Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Protein Expression Market: Expression System Estimates & Trend Analysis
8. Protein Expression Market: Product Estimates & Trend Analysis
9. Protein Expression Market: Application Estimates & Trend Analysis
10. Protein Expression Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Protein Expression Market
13. Europe Global Protein Expression Market
14. Asia Pacific Global Protein Expression Market
15. Latin America Global Protein Expression Market
16. MEA Global Protein Expression Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- QIAGEN
- Thermo Fisher Scientific Inc.
- Promega Corporation
- Agilent Technologies Inc.
- Oxford Expression Technologies
- Lucigen Corporation
- Bio-Rad Laboratories
- Merck Millipore
- Takara Bio Inc.
- New England BioLabs Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.34 Billion |
| Forecasted Market Value ( USD | $ 13.69 Billion |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
